Tixagevimab/cilgavimab for Omicron SARS-CoV-2 infection in patients with haematologic diseases

1

Tixagevimab-cilgavimab is authorized for treating Omicron SARS-CoV-2 infection in high-risk patients with hematologic malignancies.
2

Patients with hematologic malignancies have a reported 16.5% mortality rate from COVID-19, significantly higher than immunocompetent individuals.
3

In a study of 13 patients, tixagevimab-cilgavimab treatment led to increased anti-S IgG levels, indicating a positive immune response.
4

Asymptomatic patients treated with tixagevimab-cilgavimab did not develop severe COVID-19 and could continue chemotherapy.
5

The study highlights the need for effective treatments for hematologic patients, as outcomes with tixagevimab-cilgavimab varied among individuals.

Bone Marrow Transplantation

by Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Rémy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurélie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard
December 8, 2022

1